ANNX
Annexon, Inc.
A clinical-stage biopharmaceutical company developing therapies that target the complement system, the part of the immune system that helps clear damaged cells and defend against infection. Its lead programs focus on treating autoimmune and inflammatory diseases of the nervous system and eye. The company was founded in 2011 and is headquartered in Brisbane, California.
CUSIP: 03589W102HealthcareUS1 holder
Total Value
$388.6K
Total Shares
70.2K
Net Share Change
+70.2K
Activity
1 buying
Investor
Value
Shares
Weight
Change
